Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We cover all activities from target-to-clinic, and provide high quality stand-alone and integrated drug discovery and development solutions.
We operate worldwide with more than 2,800 employees. Our headquarters is located in Hamburg, Germany and our thirteen operating sites are located in Lyon and Toulouse (France), Cologne, Goettingen and Munich (Germany), Verona (Italy), Abingdon and Manchester (UK), and Branford, Princeton, Seattle and Watertown (USA).
Evotec Group comprises the affiliate companies Aptuit, Cyprotex and Just – Evotec Biologics.
· Aptuit offers a complete set of integrated drug development solutions "under one roof" and specialises in integrated CMC as well as pre-clinical and IND-enabling GLP/GMP programs.
· Cyprotex specialises in in silico and in vitro ADME-Tox and serves different industries including the pharmaceutical and biotech, personal care and cosmetics, household products, and the chemical and agrochemical industries.
·  Just – Evotec Biologics focuses on technologies to accelerate the development of biotherapeutics and substantially reduce their manufacturing cost. Core strengths are molecular design, process and product design as well as manufacturing plant design.
Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others, to develop first-in-class or best-in-class treatments for conditions with a high unmet medical need.

Sales Markets

Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Central/South America

Contact information




View All Contact Info